Crossmark

Long-term treatment persistence and maintained reduction of LDL-cholesterol levels with evolocumab over 30 months: Results from the Spanish cohort of the European prospective HEYMANS study

Crossref DOI link: https://doi.org/10.1016/j.artere.2023.04.003

Published Print: 2023-11

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Blanco Echevarría, Agustín

García Díaz, Juan De Dios

Caixas, Assumpta

Plana Gil, Núria

Rico Corral, Miguel Ángel

Bridges, Ian

Dhalwani, Nafeesa

Gatell Menchen, Sònia

Ray, Kausik K.
License Information

Text and Data Mining valid from 2023-11-01

Version of Record valid from 2024-01-25
More Information

This article is maintained by: Elsevier

Article Title: Long-term treatment persistence and maintained reduction of LDL-cholesterol levels with evolocumab over 30 months: Results from the Spanish cohort of the European prospective HEYMANS study

Journal Title: Clínica e Investigación en Arteriosclerosis (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.artere.2023.04.003

Content Type: article

Copyright: © 2023 The Author(s). Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Arteriosclerosis.

Document is current

Any future updates will be listed below